Journal of Nuclear Medicine · 2020 · 29 citations · 21 references
MedicineNuclear MedicinePharmacologyMolecular ImagingRadionuclide TherapyTherapeutic Nuclear MedicineEndocrine Tumor ImagingNeuroendocrine Tumor TherapyNeuroendocrine TumorsPeptide Receptor Radionuclide TherapySomatostatin Receptor ImagingTumor ImagingMultimodal Imaging AgentsPancreatic Neuroendocrine NeoplasmsPeptide Receptor Radionuclide Therapy ImagingRadioligand ImagingSomatostatin AnaloguesSomatostatin Receptor PetSomatostatin Receptor ScintigraphySomatostatin Receptor Therapy
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin receptor (SSTR) analogs is a common approach in advanced neuroendocrine neoplasms. Recently, SSTR antagonists have shown promising results for imaging and therapy due to a higher number of binding sites than in commonly used agonists. We evaluated PRRT with SSTR agonist <sup>177</sup>Lu-DOTATOC and antagonist <sup>177</sup>Lu-DOTA-JR11 longitudinally in an orthotopic murine pancreatic neuroendocrine neoplasm model expressing human SSTR2. Morphologic and metabolic changes during treatment were assessed using multimodal imaging, including hybrid PET/MRI and SPECT/CT. <b>Methods:</b> In vitro radioligand binding and internalization assays and cell-cycle analysis were performed. SSTR2-transfected BON cells (BON-SSTR2) were used for in vivo experiments. Tumor-bearing mice received 2 intravenous injections of 100 μL of saline, 30 MBq of <sup>177</sup>Lu-DOTATOC, or 20 MBq of <sup>177</sup>Lu-DOTA-JR11 with an interval of 3 wk. Weekly T2-weighted MRI was performed for tumor monitoring. Viability of the tumor tissue was assessed by <sup>18</sup>F-FDG PET/MRI once after PRRT. Tumor and kidney uptake of the respective radiopharmaceuticals was measured 24 h after injection by SPECT/CT. <b>Results:</b> Compared with <sup>177</sup>Lu-DOTATOC, <sup>177</sup>Lu-DOTA-JR11 treatment resulted in an increased accumulation of cells in G2/M phase. Animals treated with the SSTR antagonist showed a significant reduction in tumor size (<i>P</i> < 0.001) and an increased median survival (207 d; interquartile range [IQR], 132–228) compared with <sup>177</sup>Lu-DOTATOC (126 d; IQR, 118–129). SPECT/CT revealed a 4-fold higher median tumor uptake for the antagonist and a 3-fold higher tumor-to-kidney ratio in the first treatment cycle. During the second therapy cycle, tumor uptake of <sup>177</sup>Lu-DOTATOC was significantly lower (<i>P</i> = 0.01) whereas <sup>177</sup>Lu-DOTA-JR11 uptake remained stable. Imaging of tumor morphology indicated comparatively larger necrotic fractions for <sup>177</sup>Lu-DOTA-JR11 despite further tumor growth. These results were confirmed by <sup>18</sup>F-FDG PET, revealing the least amount of viable tumor tissue in <sup>177</sup>Lu-DOTA-JR11–treated animals, at 6.2% (IQR, 2%–23%). <b>Conclusion:</b><sup>177</sup>Lu-DOTA-JR11 showed a higher tumor-to-kidney ratio and a more pronounced cytotoxic effect than did <sup>177</sup>Lu-DOTATOC. Additionally, tumor uptake was more stable over the course of 2 treatment cycles.
21
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Massimo Falconi, Barbro Eriksson, Gregory Kaltsas et al. · Neuroendocrinology · 2016 · 1.4K citations · Full text
Medicine, Endocrinology, Oncology +17
Marianne Pavel, Dermot O’Toole, Frederico Costa et al. · Neuroendocrinology · 2016 · 1K citations